Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.
Recently, the group launched Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Zydus is also the only Indian pharma company to launch its own patented NCE – Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.
The group’s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing Director of the group.
From a turnover of Rs.250 crores in 1995, the group posted revenues of over Rs.9800 crores in FY16. The group had posted a turnover of Rs.4600 crores in FY 11, making it a billion dollar company. It aims to be a leading global healthcare provider with a robust product pipeline and aspires to post revenues of Rs.10000 crore by 2015-16 and be a research-based pharmaceutical company by 2020.
Today’s MSD is a global healthcare leader working to help the world be well. Merck & Co. Inc., Kenilworth, N.J., USA is known as MSD outside the United States and Canada. Through our prescription medicines vaccines biologic therapies and animal health products. We work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships.
MSD in India
MSD operates its human health business in India through three separate legal entities: MSD Pharmaceuticals Private Limited, Organon (India) Private Limited, and Fulford (India) Limited. Since its existence in India, the company has moved quickly in laying the foundation for a business that is differentiated by its focus through launching innovative products relevant to India. MSD in India also has presence in Animal Health via MSD Animal Health with its vaccines facility located in Pune, Maharashtra.
Key therapeutic areas
MSD in India currently operates in various therapeutic areas in human health, including Metabolics, Cardiovascular, Vaccines, Critical Care, Immunology, Virology, Oncology, Women's Health, Dermatology, Respiratory, Musculoskeletal and Primary Care, and offers a strong and diversified product portfolio of over 60 brands in total.
Commitment to India
MSD has a long term commitment to India both in terms of bringing best in class products and also making necessary investments to serve the Indian patients. MSD will continue in its endeavor to help shape the healthcare paradigms in India through initiatives like responsible pricing, integrated disease management programs; partnerships for research & access; capacity building initiatives, amongst others. In addition to setting up a sales and marketing structure to market best in class products in India, MSD is also coordinating research projects with clinical investigators in India's leading hospitals and universities, for development of new drugs to address unmet medical needs for Indian patients.
Caring for the society we serve
MSD embraces a commitment to its stakeholders, employees, neighbours, and others in the global communities where it lives and works. Its commitment is demonstrated by its work in more than 140 countries worldwide through its philanthropic initiatives and ethical business practices. In India as well, the Company has a number of Corporate Social Responsibility, Disease Management programs and Capacity building initiatives in order to better serve the interest of patients and communities.
BSV researches, develops, manufactures, and markets injectable biological, pharmaceutical, and biotech products. Its product portfolio comprises 25 brands which include plasma derivatives, monoclonals, fertility hormones, antifungals, anaesthetics, cardiovascular drugs and equine immunoglobulins / antitoxins. BSV provides its products to retail outlets and hospitals through distributors primarily in India and also internationally. In addition to its commercial operation, the Company has an extensive research and development platform working on the development of new drug delivery systems, biotechnology / recombinant therapeutics, and biological / equine products.
BSV currently has two private equity investors, Kotak Private Equity and Orbimed.
The world around us is changing fast and so is our life and our lifestyles. Given the kind of active lifestyles we are leading the concern for health and making healthier choices has become even more critical. Today, we all are on look out for newer, healthier and more wholesome options to lead healthier lives.
Zydus Wellness combines the best of healthcare, nutrition and cosmeceuticals to bring to you an array of the best wellness products to enrich your life. Our products - Sugar Free, Nutralite, Everyuth and Actilife will help nourish and nurture your life and making healthier and better you.
At Zydus Wellness we are always working towards newer, healthier and more wholesome options to lead healthier lives.
Bausch + Lomb is solely dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple yet powerful: Helping you see better to live better.
The company is one of the best-known and most respected healthcare brands in the world, offering the widest and finest range of eye health products including contact lenses and lens care products, pharmaceuticals, intraocular lenses and other eye surgery products.
Our highest priority is the well-being of the people we serve. By listening to our customers and patients, by constantly honing our innovation edge, by executing with integrity and excellence, we strive to earn the trust of our partners and stakeholders.
Over the last 150 years, Bausch + Lomb has become a global hallmark for innovation and quality. Our talented and motivated colleagues work relentlessly to invent new materials, engineer new technologies, and ultimately bring new innovations to help people see better to live better.
We Market Three Broad Categories of Products
Vision Care: Our contact lens offerings span the entire spectrum of wearing modalities and include such well-known brand names as PureVision and Soflens. Our lens care products include Biotrue and renu brand of chemical disinfectants for soft contact lenses as well as the Boston line of products for cleaning GP contact lenses.
Pharmaceuticals: Our products treat a wide range of eye conditions including dry eye and retinal diseases. We offer proprietary medicines available by prescription, over-the-counter eye drops and other medications. Leading OTC products include the Ocuvite brand of ocular vitamins and Artelac products for dry eye.
Cataract and Vitreoretinal Surgery: We offer a full suite of products including intraocular lenses and delivery systems featuring the Crystalens, SofPort and Akreos brands of IOLs, the Stellaris and Millennium lines of phacoemulsification equipment, and other surgical instruments and devices, including the Storz line of instruments.
The Pharmaceuticals Division focuses on prescription products, especially for women’s healthcare and cardiology, and also on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises of the Diagnostic Imaging business which markets contrast agents.
With our innovative products, we seek to achieve a significant therapeutic benefit for patients, while at the same time satisfying the growing requirements of physicians.
On a global level, in the medium term, our recently launched products such as Xarelto™, Eylea™, Stivarga™, Xofigo™ and Adempas™ in particular should contribute to increased sales. To safeguard our growth in the long term, we will be further expanding our early-stage research activities and driving forward the clinical development of active ingredient candidates discovered in-house. Moreover, we will continue to systematically supplement our development portfolio by means of licensing agreements and acquisitions.
In India, the Pharmaceuticals Division markets products under the joint venture company Bayer Zydus Pharma.
Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products, Advance Intermediates, Fine Ingredients, Crop Science Ingredients, Life Science Chemicals and Nutritional Products. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services.
Our success is an outcome of strategic focus on the pharmaceuticals and life sciences industry, moving up the pharmaceutical value chain for products and services across geographies, constantly investing in various growth platforms and promoting a culture of innovation.
We are engaged in continuous improvement of products and processes to enhance the quality of production and cost competitiveness in order to build value for our customers. Jubilant Life Sciences serves its customers globally with sales in over 100 countries and ground presence in India, North America, Europe and China. We are well recognised as a ‘Partner of Choice’ by leading life sciences companies worldwide. Jubilant has relationship with 19 of Top 20 pharmaceutical companies and 6 amongst top 10 agrochemical companies across the globe.
Over the years, Jubilant Life Sciences has extended its footprint beyond India in the USA, Canada, Europe, and other countries across the globe. We have also expanded the business by building capabilities internally, through strategic expansions and acquisitions. This resulted in a network of 7 world class manufacturing facilities in India and 4 in North.
Ferring Pharmaceuticals is a research-driven, biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopaedics.
The company's research activities and products are connected by a common focus of providing tailored treatments that work on the body's own terms, enabling doctors to combat numerous diseases and medical conditions.
Ferring has its own manufacturing facilities in several European countries, in South America, Israel, India and China. It is also currently building new facilities in the USA. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring's marketing, medical services and sales teams, led by the corporate headquarters in Saint-Prex, Switzerland, operate from nearly 60 countries and employ over 6,000 people throughout the world, while treatments are available in 110 countries. This expansion has allowed Ferring to maintain a double-digit annual growth rate over the last two decades.
Supplier, exporter and manufacturer of pharmaceuticals formulation, aminophylline, ciprofloxacin, ranitidine, ibuprofen, metronidazole, norfloxacin.
At Novo Nordisk, we are driving change to defeat diabetes and other serious chronic conditions.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries.